

**In the United States Patent and Trademark Office**

Application No.: Not assigned  
Filed: Filed herewith  
Title: Quantification of Aortoiliac Endoluminal Irregularity  
Applicant(s): Raghav Raman  
Examiner: Not yet assigned  
Art Unit: Not yet assigned

Mailed 11-26-03  
Palo Alto, CA

**Information Disclosure Statement**

Commissioner of Patents and Trademarks  
Washington, District of Columbia 20231

Dear Sir or Madam:

Attached is a completed Form PTO-1449 and copies of the pertinent parts of the references cited thereon. It is requested that the document(s) on the enclosed form be made of record.

**Part I (Authority)**

This statement is filed pursuant to:

☒ 37 C.F.R. § 1.97(b).

This information disclosure statement is filed either (1) within three months of the filing date of the national applications; (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or (3) before the mailing date of a first office action on the merits, whichever event occurs last.

Accordingly, this information disclosure statement requires no fee and no certification.

☐ 37 C.F.R. § 1.97(c).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of either (1) a final action under 37 C.F.R. § 1.113 or (2) a notice of allowance under 37 C.F.R. § 1.311.

Accordingly, this information disclosure statement requires either the fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) (\$240), or a certification according to 37 C.F.R. § 1.97(e).

☐ 37 C.F.R. § 1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(c).

Accordingly, this information disclosure statement requires the petition fee specified in 37 C.F.R. § 1.17(i)(1) to consider an information disclosure statement under 37 C.F.R. § 1.97(d) (\$130), a certification according to 37 C.F.R. § 1.97(e), and a petition requesting consideration of the information disclosure statement.

**Conditional Petition**

It is respectfully requested that this information disclosure statement be considered, good cause being presented in Part III herein (certification). please treat this paper as the required petition.

If this statement crosses in the mail with an office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record.

To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

## Part II (Payment)

A check is enclosed as indicated:

- ☒ (X) No fee is due.
- ☐ ( ) The fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c) is enclosed (\$240).
- ☐ ( ) The petition fee specified in 37 C.F.R. § 1.17(i)(1) to consider an information disclosure statement under 37 C.F.R. § 1.97(d) is enclosed (\$130).

## Part III (Certification)

Pursuant to 37 C.F.R. § 1.97(e), I certify:

- ☒ (X) No certification is necessary.
- ☐ ( )
  - (1) Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement.
  - ☐ ( ) The "communication from a foreign patent office" referred to in the certification is an International Search Report, possibly issued by the U.S. Patent and Trademark Office in its capacity as an International Search Authority or International Preliminary Examining Authority.
  - ☐ ( ) The "counterpart foreign application" referred to in the certification corresponds to an ancestor or descendent application of the application for which this information disclosure statement is filed.
- ☐ ( ) (2) No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c), more than three months prior to the filing of the statement.

## Part IV (Additional Statement)

An additional statement regarding these items of information ( ) is, (X) is not, enclosed.

Copies of the cited art (X) are enclosed, ( ) are of record in parent application Serial No. \_\_\_\_\_ and will be provided if the Examiner deems it convenient.

Dated: 11-26-03

Respectfully submitted,



Ron Jacobs, Ph.D.  
Reg. No. 50,142  
2345 Yale Street, 2<sup>nd</sup> Floor  
Palo Alto, CA 94306  
tel: (650) 424-0100  
fax: (650) 424-0141

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE										ATTY. DOCKET NO. S02-270/US					SERIAL NO. Not yet assigned									
<b>LIST OF PRIOR ART CITED BY APPLICANT</b> (Use several sheets if necessary)															APPLICANT Raghav Raman									
															FILING DATE Filed Herewith					GROUP Not yet assigned				
<b>U.S. PATENT DOCUMENTS</b>																								
EXAMINER INITIAL				DOCUMENT NUMBER				DATE				NAME				RELEVANT INFORMATION								
		A																						
		B																						
		C																						
		D																						
		E																						
<b>FOREIGN PATENT DOCUMENTS</b>																								
		2-letter code		DOCUMENT NUMBER				DATE				COUNTRY				TRANSLATION								
																YES		NO						
		F																						
		G																						
<b>OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)</b>																								
		H		Tillich M, Bell RE, Paik DS, Fleischman D, Sofilos MC, Logan LJ, Rubin GD., Iliac Arterial injuries after Endovascular repair of Abdominal Aneurysms: Correlation with Iliac Curvature and Diameter. Radiology 2001 Apr.;219(1):129-36.																				
		I		Hatakeyama T, Shiegematsu H, Muto T., "Risk Factors for Rupture of Abdominal Aortic Aneurysm based on Three-dimensional Study", J Vasc. Surg. 2001 Mar; 33 (3):453-6																				
		J		White RA, Donayre CE, Walot I, Woody JD, Kim NI, Kopchok GE., "Computed Tomography Assessment of Abdominal Aortic Aneurysm Morphology after Endograft Exclusion", Journal of Vascular Surgery. 2001; 33:S1-10.																				
		K		Tillich M, Hill B B, Paik D S, Petz K, Napel S, Zarins C K, Rubin G D, "Prediction of Aortoiliac Stent-Graft Length: Comparison of Measurement Methods", Vascular and Interventional Radiology 2001;220:475-483																				
		L		Ravhon R. Adam D. Zelmanovitch L., "Validation of Ultrasonic Image Boundary Recognition in Abdominal Aortic Aneurysm", IEEE Trans Med Imaging 2001 AUG;20(8):751-63.																				
		M		Leotta DF, Paun M, Beach KW, Kohler TR, Zierler RE, Strandness DE Jr., Measurement of Abdominal Aortic Aneurysms with Three-dimensional Ultrasound Imaging: Preliminary Report, J. Vascular Surg. 2001 Apr;33(4):700-7																				
		N		Zarins et al. (2001) in a paper entitled "The AneuRx stent graft: four-year results and worldwide experience" and published in J Vasc Surg 33:S135-145																				
				Holzenbein et al. (2001) in a paper entitled "Midterm durability of abdominal aortic aneurysm endograft repair: a word of caution" and published in J Vasc Surg 33:S46-54																				
				Makaroun et al. (2001) in a paper entitled "Is proximal aortic neck dilatation after endovascular aneurysm exclusion a cause for concern?" and published in J Vasc Surg 33:S39-45																				
<b>EXAMINER</b>										<b>DATE CONSIDERED</b>														
* <b>EXAMINER:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.																								